Evidence-Based. Clearly Delivered.
Evidence-Based. Clearly Delivered.
Recent legal developments continue to shape access to medication abortion in the United States, particularly for mifepristone, a key component of the most commonly used abortion regimen. In May 2026, the U.S. Supreme Court issued an emergency order allowing mifepristone to continue to be prescribed via telehealth and dispensed by mail while ongoing litigation proceeds. This ruling temporarily blocks a federal appeals court decision that would have reinstated stricter in‑person prescribing requirements, thereby preserving nationwide access for now.
Mifepristone is used in combination with misoprostol for medication abortion, which now accounts for nearly two‑thirds of abortions in the United States. The regimen involves mifepristone to block progesterone, followed 24 to 48 hours later by misoprostol to induce uterine contractions. Since 2021, the FDA has permitted telehealth prescribing and mail distribution of mifepristone, expanding access, particularly in areas with limited abortion services. The current legal challenge centers on whether this regulatory change was appropriately supported by safety data.
The litigation originates from a lawsuit filed by the state of Louisiana, which argues that removing the in‑person dispensing requirement undermines state abortion restrictions and may pose safety risks. However, major medical organizations counter that extensive evidence, over 100 studies, supports the safety and efficacy of mifepristone, with serious complications considered rare. Opponents of the FDA policy also contend that broader access increases costs related to complications, though these claims remain disputed within the medical community.
The Supreme Court’s brief order did not include a detailed rationale, a common feature of emergency rulings, but it indicates that the status quo will remain until the case is further reviewed in lower courts. A final resolution could take months and may ultimately return to the Supreme Court. The case also raises broader implications for federal drug regulation, as pharmaceutical manufacturers warn that allowing state-by-state challenges to FDA decisions could create instability across the drug approval system.
Because the Supreme Court’s emergency stay merely pauses the lower court’s restrictions while the litigation proceeds, a final, definitive decision on nationwide telehealth and mail-order access to mifepristone is not expected until the case winds back through the Fifth Circuit and returns to the high court for a merit-based ruling, likely in late 2027 or early 2028.
Systemic Reivew: Efficacy of Misoprostol Alone for First-Trimester Medical Abortion
“The Abortion Case the Supreme Court Has Been Waiting For?”
Louisiana v. FDA, No. 26-30203 (5th Cir. 2026)
The contents of this Site, such as text, graphics, images, information obtained from The ObG Project’s licensors, and other material contained on the Site (“Content”) are for informational purposes only. The Content is not intended to be a substitute for professional legal or medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read on the Site!
If you think you may have a medical emergency, call your doctor or 911 immediately. The ObG Project does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site. Reliance on any information provided by The ObG Project, The ObG Project employees, others appearing on the Site at the invitation of The ObG Project, or other visitors to the Site is solely at your own risk.
The Site may contain health- or medical-related materials that are sexually explicit. If you find these materials offensive, you may not want to use our Site.
Children’s Privacy
We are committed to protecting the privacy of children. You should be aware that this Site is not intended or designed to attract children under the age of 13. We do not collect personally identifiable information from any child we reasonably believe is under the age of 13.
Continue with ObGFirst™
Read the full article, unlock patient-friendly tools, and access subscriber resources across the site.
Get ObGFirst™ for only $9/mo
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
